NCT03065530

Intravenous Dexmedetomidine for Cesarean Section

Efficacy and Safety of Dexmedetomidine Combined With Butorphanol Tartrate for Postoperative Analgesia and Breastfeeding in Cesarean Section

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: The First Affiliated Hospital with Nanjing Medical University · Academic / Other
• Sex: Female
• Age: 24 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Nervous, anxiety, fear and other psychological reactions always appears in parturients during cesarean section. This study intends to investigate the effectiveness and safety of dexmedetomidine combined with butorphanol tartrate for postoperative analgesia and breastfeeding after caesarean section.

Conditions

• Breast Feeding
• Analgesia Obstetrical
• Postoperative Pain

Interventions

Type	Name	Description
DRUG	Normal Saline	Drug: Normal saline control group receive NS after delivery. Drug: butorphanol tartrate PCA: butorphanol tartrate after cesarean section.
DRUG	Dexmedetomidine 0.03ug/kg/h	Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.03ug/kg/h Dexmedetomidine after cesarean section.
DRUG	Dexmedetomidine 0.05ug/kg/h	Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.05ug/kg/h Dexmedetomidine after cesarean section.
DRUG	Dexmedetomidine 0.08ug/kg/h	Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.08ug/kg/h Dexmedetomidine after cesarean section.

Timeline

• Start date: 2017-02-07
• Primary completion: 2017-09-30
• Completion: 2017-10-05
• First posted: 2017-02-28
• Last updated: 2020-01-13
• Results posted: 2020-01-13

Locations

1 site across 1 country: China